REG - Cizzle Biotechnology - Final results for the year ended 31 December 2025

Cizzle Biotechnology HoldingsAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260430:nRSd4787Ca&default-theme=true

RNS Number : 4787C  Cizzle Biotechnology Holdings PLC  30 April 2026

30 April 2026

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Final results for the year ended 31 December 2025

Cizzle Biotechnology, the UK based diagnostics developer of early cancer
tests, announces the publication of the Company's Annual Report and Financial
Statements for the year ended 31 December 2025 (the "Annual Report").

The Annual Report is available via
http://www.rns-pdf.londonstockexchange.com/rns/4787C_1-2026-4-29.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/4787C_1-2026-4-29.pdf)  and
will shortly be available to view on the on the National Storage Mechanism
(NSM) and the Company's website: https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                    +44(0) 20 3328 5656
 John Depasquale (Corporate Finance)
 Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited  +44(0) 20 3934 6632
 Tim Metcalfe
 Florence Staton

 

About Cizzle Biotechnology

 

The CIZ1B biomarker is a naturally occurring variant of the cell nuclear
protein CIZ1, which is linked with the preservation of epigenetic integrity.
 CIZ1B is highly associated with the presence of early-stage lung cancer and
can be measured in small quantities of blood.  The Company has developed
CIZ1B into a non-invasive, cost-effective blood test to help in the early
detection of lung cancer and has now entered commercial royalty-bearing
arrangements to license its proprietary technology, and into collaborations
with centres of excellence in cancer care.  Cizzle was admitted to the
Standard segment of the main market of the London Stock Exchange in May
2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

 

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR EAPLNADLKEFA



            Copyright 2019 Regulatory News Service, all rights reserved